The effect of adjuvant chemotherapy on plasma TAT and F 1+2 levels in patients with breast cancer

TOPCU T. O., Kavgaci H., CANYILMAZ E., ÖREM A., YAMAN H., US D., ...More

BIOMEDICINE & PHARMACOTHERAPY, vol.73, pp.19-23, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 73
  • Publication Date: 2015
  • Doi Number: 10.1016/j.biopha.2015.05.003
  • Journal Name: BIOMEDICINE & PHARMACOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.19-23
  • Keywords: Thrombin-antithrombin, Prothrombin fragment 1+2, Breast cancer, VENOUS THROMBOEMBOLISM, D-DIMER, VIENNA CANCER, PROTHROMBOTIC STATE, LUNG-CANCER, RISK, COAGULATION, ACTIVATION, PROTEIN, MARKER
  • Karadeniz Technical University Affiliated: Yes

Abstract

Introduction: Increased thromboembolic disorders and chemotherapy-induced thromboembolic events are well known phenomena in patients with breast cancer. Antithrombin III (AT III) inactivates thrombin, resulting in increased thrombin-antithrombin (TAT) levels. Activated factor X cleaves prothrombin and thrombin, resulting in increased levels of prothrombin fragment 1 + 2 (F 1 + 2). Increased TAT and F 1 + 2 levels show coagulation activation. The aim of this study was to examine plasma levels of TAT and F 1 + 2 and the effect of anthracycline-based chemotherapy on plasma TAT and F 1 + 2 in patients with operable breast cancer.